首页> 美国卫生研究院文献>Cancer Medicine >A double‐blind randomized multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
【2h】

A double‐blind randomized multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

机译:帕洛诺司琼与格拉司琼联合地塞米松和福沙泼尼联合预防蒽环类和环磷酰胺类乳腺癌患者化疗引起的恶心和呕吐的双盲多中心三期研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To investigate whether palonosetron is better than granisetron in preventing chemotherapy‐induced nausea and vomiting (CINV) in a three‐drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC‐based regimen).
机译:调查在合并蒽环类和环磷酰胺治疗的乳腺癌患者中,帕洛诺司琼与地塞米松和福沙普瑞特(Fos)的三药联用在预防化疗引起的恶心和呕吐(CINV)方面​​是否优于格拉司琼(AC方案) 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号